drugset / Trial / NCT00276094

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

NCT00276094

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.

Timeline

Start
2006-01
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ospemifene Other / unclassified 30 mg Oral
Subject Ospemifene Other / unclassified 60 mg Oral
Background K-Y® Brand Jelly Unknown